Results

1–9 of 9 results for AMD non-neovascular

Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Impact of Baseline Imbalances on the Efficacy of Pegcetacoplan for the Treatment of GA: A Post Hoc Analysis of OAKS, DERBY, and FILLY
Sunir J. Garg, MD, FACS, FASRS
Updates from the Field
2022
Therapeutic Horizons for Dry AMD
Robert L. Avery, MD
Updates from the Field
2019
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018
Common Age-Related Macular Degeneration Genetic Risk Variants and Geographic Atrophy Lesion Growth in the Chroma and Spectri Phase 3 Lampalizumab Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2018
Direct-to-Consumer Marketing by U.S. Cell Therapy Clinics for Retinal Conditions
Ajay E Kuriyan, MD, MS
Annual Meeting Talks
2018
Progression of Visual Function Endpoints in Early and Intermediate Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Annual Meeting Talks
2018
Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated With Intravitreal Aflibercept or Ranibizumab in the VIEW studies
Robert L. Avery, MD
On Demand Cases, Courses, and Papers
2017